Table 2.
The top enriched GO pathways (pathway size <100; enrichment p-value < 0.1) which also significantly correlated with treatment response (|correlation|> 0.7; correlation p-value < 0.01)
| GO Pathway | Treatment response correlation | GO-Enrichment Pvalue | M_DEG |
|---|---|---|---|
| Heparan sulfate proteoglycan metabolic process | 0.81 | 2.50E-06 | EXTL3, HPSE, NDST1, SULF2 |
| Cellular carbohydrate catabolic process | 0.86 | 0.00135 | GK5, MGAM, PYGL |
| Positive regulation of CD4-positive, alpha-beta T cell activation | 0.90 | 0.00268 | CD55, CD83 |
| Hair follicle development | 0.80 | 0.00273 | HPSE, LAMA5, TGM3 |
| Molting cycle process | 0.80 | 0.00273 | HPSE, LAMA5, TGM3 |
| Hair cycle process | 0.80 | 0.00273 | HPSE, LAMA5, TGM3 |
| Skin epidermis development | 0.80 | 0.00283 | HPSE, LAMA5, TGM3 |
| Positive regulation vascular endothelial growth factor production | 0.74 | 0.00317 | HPSE, SULF2 |
| Glucan catabolic process | 0.88 | 0.00369 | MGAM, PYGL |
| Cellular polysaccharide catabolic process | 0.88 | 0.00397 | MGAM, PYGL |
| Regulation of vascular endothelial growth factor production | 0.79 | 0.00425 | HPSE, SULF2 |
| Polysaccharide catabolic process | 0.88 | 0.00454 | MGAM, PYGL |
| Vascular endothelial growth factor production | 0.76 | 0.00485 | HPSE, SULF2 |
| Proteoglycan biosynthetic process | 0.76 | 0.01521 | EXTL3, NDST1 |
| Myeloid cell activation involved in immune response | 0.78 | 0.01734 | F2RL1, SBNO2 |
| Glycosaminoglycan catabolic process | 0.76 | 0.01789 | HPSE, PGLYRP1 |
| Cellular glucan metabolic process | 0.75 | 0.03104 | MGAM, PYGL |
| Glucan metabolic process | 0.75 | 0.03104 | MGAM, PYGL |
| Glomerular epithelial cell development | 0.88 | 0.03312 | IQGAP1 |
| Positive regulation of mitochondrial fission | 0.79 | 0.03312 | PINK1 |
| Manganese ion transport | 0.73 | 0.03961 | SLC11A1 |
| Regulation of hair follicle development | 0.78 | 0.04284 | HPSE |
| Cellular polysaccharide metabolic process | 0.72 | 0.04295 | MGAM, PYGL |
| Nucleus localization | 0.76 | 0.07144 | TACC3 |
| Glycogen catabolic process | 0.88 | 0.08388 | PYGL |
| Peptide cross-linking | 0.74 | 0.09616 | TGM3 |
| Cell proliferation in forebrain | 0.85 | 0.09616 | TACC3 |
| Regulation of CD4-positive, alpha-beta T cell activation | -0.90 | 0.00485 | CD55, CD83 |
| Aminoglycan catabolic process | -0.75 | 0.02074 | HPSE, PGLYRP1 |
| Regulation of oxidative phosphorylation | -0.76 | 0.03312 | PINK1 |
| Nuclear pore organization | -0.80 | 0.03637 | TMEM33 |
| Regulation of natural killer cell differentiation | -0.71 | 0.03961 | PGLYRP1 |
| Pore complex assembly | -0.72 | 0.03961 | TMEM33 |
| Glycoprotein catabolic process | -0.77 | 0.04284 | HPSE |